Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma - Contacts and Locations

Home

Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

This study has been completed.
Information provided by Genmab

Please refer to this study by its ClinicalTrials.gov identifier: NCT00092274

Locations


United States, Iowa
	University of Iowa Hospitals and Clinics
	Iowa City, Iowa, United States, 52242

Sponsors and Collaborators

Genmab